- Mechoulam R. & Parker L.A. 2013. The endocannabinoid system and the brain. Annu. Rev. Psychol; 64: 21–47.
- Cristino L. et al. 2020. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol; 16(1): 9-29.
- Chang A.E. et al. 1981. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and Cytoxan chemotherapy. Cancer; 47: 1746–1751.
- McCabe M. et al. 1988. Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Invest. New Drugs; 6: 243–246.
- Riggs P.K. et al. 2012. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res; 1431: 46–52.
- Beal J.E. et al. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage; 10(2): 89-97.
- Notcutt W. et al. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ’N of 1’ studies. Anaesthesia; 59(5): 440–452.
- Rog D.J. et al. 2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology; 65(6): 812–819.
- Abrams D.I. et al. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology; 68(7): 515–521.
- Boland E.G. et al. 2020. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Support Palliat Care; 10(1): 14-24.
- Boyaji S. et al. 2020. The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Curr Pain Headache Rep; 24(2): 4.
- Wade D.T. et al. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler; 12(5): 639–645.
- Conte A. et al. 2009. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur. J. Pain; 13(5): 472–477.
- Collin C. et al. 2010. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res; 32(5): 451–459.
- Fox P. et al. 2004. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology; 62(7): 1105–1109.
- Hildebrand A. et al. 2019. Cannabis use for symptom relief in multiple sclerosis: a cross-sectional survey of webinar attendees in the US and Canada. Mult Scler Relat Disord; 38: 101516.
- Mueller-Vahl K.R. et al. 2003. Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry; 64(4): 459–465.
- Muller-Vahl K.R. et al. 2002. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry; 35(2): 57–61.
- Milosev L.M. et al. 2019. Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis Cannabinoid Res; 4(4): 265-274.
- Consroe P. et al. 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci; 30(4): 277–282.
- Hsu K. et al. 2020. Potential role of cannabidiol for seizure control in a patient with recurrent glioma. J Clin Neurosci; 71: 275-276.
- Téllez-Zenteno J.F. et al. 2020. The Use of Cannabis as a Treatment for Epilepsy in Adult Patients: Are Side Effects a Limitation of Use? J Clin Neurophysiol; 37(1): 9-14.
- Téllez-Zenteno J.F. & Hernández-Ronquillo L. 2020. Medical Cannabis as a Treatment for Patients With Epilepsy, Sleep Disorders, and Posttraumatic Stress Disorder. J Clin Neurophysiol; 37(1): 1.
- Esfandyari T. et al. 2007. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver. Physiol; 293(1): 137–145.
- Naftali T. et al. 2013. Cannabis induces a clinical response in patients with crohn’s disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol; 11(10): 1276–1280.
- Naftali T. & Dor M. 2020. Cannabis for the Treatment of Inflammatory Bowel Disease: A True Medicine or a False Promise? Rambam Maimonides Med J; 11(1): e0008.
- Pandey S. et al. 2020. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement Ther Med; 48: 102242.
- Wong B.S. et al. 2011. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with non-constipated irritable bowel syndrome. Gastroenterology; 141(5): 1638–1647.
- Tomida I. et al. 2006. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma; 15(5): 349–353.
- Merritt J.C. et al. 1981. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J. Pharm. Pharmacol; 33(1): 40–41.
- Sarris J. et al. 2020. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry; 20(1): 24.
- Choi S. et al. 2020. Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. J Clin Neurophysiol; 37(1): 39-49.
